Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion

British Journal of Pharmacology

Volumn 126, Issue 8, 1999, Pages 1751-1760

  Haworth, Duncan ^a   Rees, Amanda ^a   Alcock, Peter J ^a   Wood, Linda J ^a   Dutta, Anand S ^a   Gormley, James J ^a   Jones, Huw B ^a   Jamieson, Alec ^a   Reilly, Christopher F ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

4 1; Cell adhesion; Delayed type hypersensitivity; Inflammation; Integrin; Leukocyte recruitment; VLA 4

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA1 INTEGRIN; CYCLOPEPTIDE; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; OVALBUMIN; OXAZOLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CHO CELL; CONTACT ALLERGY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG POTENCY; DRUG STRUCTURE; EDEMA; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T CELL LEUKEMIA; T LYMPHOBLAST;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL ADHESION; CHO CELLS; CRICETINAE; DERMATITIS, CONTACT; FEMALE; FIBRONECTINS; HUMANS; HYPERSENSITIVITY, DELAYED; INFLAMMATION; INTEGRIN ALPHA4BETA1; INTEGRINS; INTERCELLULAR ADHESION MOLECULE-1; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, T-CELL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OVALBUMIN; OXAZOLONE; PEPTIDES; RATS; RECEPTORS, LYMPHOCYTE HOMING; T-LYMPHOCYTES; TRANSFECTION;

EID: 0032901774     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702511     Document Type: Article

References (41)

1. Anderson, D.C., Schmalsteig, F.C., Finegold, M.J., Hughes, B.J., Rothlein, R., Miller, L.J., Kohl, S., Tosi, M.F., Jacobs, R.L., Waldrop, T.C., Goldman, A.S., Shearer, W.T. & Springer, T.A, (1985). The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: Their quantitative definition and relation to leukocyte dysfunction and clinical features. J. Infectious Dis., 152, 668-689.
2. Bochner, B.S., Luscinskas, F.W., Gimbrone, M.A., Newman, W., Sterbinsky, S.A., Derse-Anthony, C.P., Klunk, D. & Schleimer, R.P. (1991). Adhesion of human basophils, eosinophils and neutrophils to interleukin 1-activated human vascular endothelial cells: Contributions of endothelial cell adhesion molecules. J. Exp. Med. 173, 1553-1556.
3. Cannella, B. & Raini, C.S. (1995). The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol., 37, 424-435.
4. 1 interaction with connecting segment I and vascular cell adhesion molecule. J. Biol. Chem., 269, 18668-18673.
5. Chisholm, P.L., Williams, C.A. & Lobb, R.R. (1993). Monoclonal antibodies to the integrin α-4 subunit inhibit the murine contact hypersensitivity response. Eur. J. Immunol., 23, 682-688.
6. Clements, J.M., Newham, P., Shepherd, M., Gilbert, R., Dudgeon, T.J., Needham, L.A., Edwards, R.M., Berry, L., Brass, A. & Humphries, M.J. (1994). Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. J. Cell Sci., 107, 2127-2135.
7. Doyle, P.M., Harris, J.C., Moody, C.M., Sadler, P.J., Sims, M., Thornton, J.M., Uppenbrink, J. & Viles, J.H. (1996). Solution structure of a biologically active cyclic LDV peptide analogue containing a type II' β-turn mimetic. Int. J. Peptide Protein Res., 47, 427-436.
8. Elices, M.J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M.E. & Lobb, R.R. (1990). VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell, 60, 577-584.
9. Elices, M.J., Tamraz, S., Tollefson, V. & Vollger, L.W. (1993). The integrin VLA-4 mediates leukocyte recruitment to skin inflammatory sites in vitro. Clin. Exp. Rheumatol., 11, S77-S80.
10. Elices, M.J., Tsai, V., Strahl, D., Goel, A.S., Tollefson, V., Arrhenius, T., Wayner, E.A., Gaeta, F.C.A., Fikes, J.D. & Firestein, G.S. (1994). Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J. Clin. Invest., 93, 405-416.
11. Ferguson, T.A., Mizutani, H. & Kupper, T.S. (1991). Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo. Proc. Natl. Acad. Sci. U.S.A., 88, 8072-8076.
12. Fukuda, T., Fukushima, Y., Numao, T., Ando, N., Arima, M., Nakajima, H., Sagara, H., Adachi, T., Motojima, S. & Makino, S. (1996). Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am. J. Respir. Cell Mol. Biol., 14, 84-94.
13. - T cell binding to fibronectin. Int. J. Peptide Protein Res., 43, 417-424.
14. Hemler, M.E., Huang, C., Takada, Y., Schwarz, L., Strominger, J.I., & Clabby, M.L. (1987). Characterisation of the cell surface heterodimer VLA-4 and related peptides. J. Biol. Chem., 262, 11478-11485.
15. 4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Clin. Invest., 100, 3083-3092.
16. Issekutz, T.B. (1993). Dual inhibition of VLA-4 and LFA-1 maximally inhibits cutaneous delayed-type hypersensitivity-induced inflammation. Am. J. Pathol., 143, 1286-1293.
17. 1 peptide antagonist as potential anti-inflammatory agents. J. Med. Chem., 40, 3359-3368.
18. 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol., 58, 1-10.
19. Komoriya, A., Green, L.J., Mervic, M., Yamada, S.S., Yamada, K.M. & Humphries, M.J. (1991). The minimal essential sequence for a major cell type-specific adhesion site (CS-1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J. Biol. Chem., 266, 15075-15079.
20. 1. J. Biol. Chem., 269, 4005-4011.
21. 4 integrin antagonist peptide. J. Immunol., 158, 4180-4186.
22. Miyake, K., Weissman, I.L., Greenberger, J.S. & Kincade, P.W. (1991). Evidence for a role of the integrin VLA-4 in lymphohemopoiesis. J. Exp. Med., 173, 599-607.
23. Molossi, S., Elices, M., Arrhenius, T., Diaz, R., Coulber, C. & Rabinovitch, M. (1995). Blockade of Very Late Antigen-4 binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J. Clin. Invest., 95, 2601-2610.
24. 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J. Immunol., 149, 1424-1431.
25. 1 integrin-mediated cell adhesion. J. Biol. Chem., 268, 20352-20359.
26. Osborn, L., Hession, C., Tizard, R., Vassallo, C., Luhowskyj, S., Chi-Rosso, G. & Lobb, R. (1989). Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lympbocytes. Cell. 59, 1203-1211.
27. 7 integrin mediates B cell binding to fibronectin and vascular cell adhesion molecule-1. J. Immunol., 151, 2471-2483.
28. Prater, C.A., Plotkin, J., Jaye, D. & Frazier, W.A. (1991). The properdin-like type-1 repeats of human thrombospondin contain a cell attachment site. J. Cell Biol., 112, 1031-1040.
29. Pretolani, M., Ruffie, C., Lapa e Silva, J-R., Joseph, D., Lobb, R.R. & Vargaftig, B.B. (1994). Antibody to Very Late Antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J. Exp. Med., 180, 795-805.
30. Ross, L., Hassman, F. & Molony, L. (1992). Inhibition of MOLT-4-endothelial adherence by synthetic peptides from the sequence of ICAM-1. J. Biol. Chem., 267, 8537-8543.
31. Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 12, 697-715.
32. Sharar, S.R., Winn, R.K. & Harlan, J.M. (1995). The adhesion cascade and anti-adhesion therapy: An overview. Springer Semin. Immunopathol., 16, 359-378.
33. Smith, C.W., Marlin, S.D., Rothlein, R., Toman, C. & Anderson, D.C. (1989). Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule in facilitating adherence and transendothelial migration of human neutrophils in vitro. J. Clin. Invest., 83, 2008-2017.
34. 1 integrin receptor interactions through library synthesis and screening. Bioorg. Med. Chem. Lett., 8, 2297-2302.
35. Tamraz, S., Arrhenius, T., Chiem, A., Forrest, M.J., Gaeta, F.C.A., He, Y.-B., Lei, J., Maewal, A., Phillips, M.L., Vollger, L.W. & Elices, M.J. (1995). Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin. Spinger Semin. Immunopathol., 16, 437-441.
36. Tarayre, J.P., Barbara, M., Aliaga, M. & Tisne-Versailles. J. (1990). Comparative actions of immunosuppressants, glucocorticoids and non-steroidal anti-inflammatory drugs on various models of delayed hypersensitivity and on a non-immune inflammation in mice. Arzneim-Forsch./Drug Res., 40, 1125-1131.
37. 4 integrins. J. Immunol., 158, 1710-1718.
38. Viles, J.H., Mitchell, J.B.O., Gough, S.L., Doyle, P.M., Harris, J., Sadler, P.J. & Thornton, J.M. (1996). Multiple solution conformations of the integrin-binding cyclic pentapeptide cyclo(-Ser-D-Leu-Asp-Val-Pro-). Analysis of the (φ,ψ) space available to cyclic pentapeptides. Eur. J. Biochem., 242, 352-362.
39. Wayner, E.A., Garcia-Pardo, A., Humphries, M.J., McDonald, J.A. & Carter, W.G. (1989). Identification and characterisation of the T-lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J. Cell Biol., 109, 1321-1330.
40. Zeidler, A., Brauer, R., Thoss, K., Bahnsen, J., Heinrichs, V., Jablonski-Westrich, D., Wroblewski, M., Rebstock, S. & Hamann, A. (1995). Therapeutic effects of antibodies against adhesion molecules in murine collagen type II-induced arthritis. Autoimmunity, 21, 245-252.
41. 1 integrin receptor. J. Biol. Chem., 269, 12325-12331.